HONG KONG SAR – Media OutReach – 15 March 2022 – Due to the impact of the current epidemic, people are paying more attention to the importance of health. Given this, Neuron Physiotherapy & Sports Injury Centre introduces the dynamic neuromuscular stabilization function training method, to debunk the misunderstanding of physiotherapy, and to provide a practical and effective radical solution for ‘superficial’ health treatments. This training method enables athletes to find the roots of physical exertion problems, to eliminate the chance of injury and strain.

Dynamic neuromuscular stabilization is an innovative trend in rehabilitation therapy and sports training. It is a set of neurodevelopmental system-based assessments and remodeling of the motor system invented by Professor Pavel Kolar of the Prague School. The professional physiotherapists of the ‘Rehabilitation Square’ also have expertise in sports physiotherapy training.

Through dynamic analysis and nervous system tests, physiotherapists analyze and explore the large and small muscles with exertion problems, to find the roots of the problem. This method can effectively prevent and treat neuromuscular pain, improve the state of athletes, correct and improve exercise postures through exercise therapy.

As the epidemic is raging, the public spends most of their time at home. Given this, ‘Rehabilitation Square’ will regularly provide several mild to moderate training for their customers in addition to the introduction of new physiotherapy techniques. By doing so, customers can conveniently participate in exercises at home. Stretching exercises can relieve neck and arm pain from long-term exposure to electronic products, meanwhile strengthening the body. Furthermore, the ‘Rehabilitation Workshop’ also provides effective home treatment and inquiries for patients who suffer from “injection site pain” after vaccination.

Moreover, the Rehabilitation Workshop also provides on-site physiotherapy services and on-site physiotherapy consultation services to help patients who need regular physiotherapy to begin the road to recovery.

About Neuron Physiotherapy & Sports Injury Centre

Neuron Physiotherapy & Sports Injury Centre a Hong Kong physiotherapy platform that integrates Chinese and Western medical concepts as a consultation direction for the treatment of various pain disorders and diseases, such as frozen shoulders, and high & low shoulders. In physiotherapy, exercise therapy is also a commonly used method. Rehabilitation Square also provides exercise therapy such as sports massage and stretching therapy. All physiotherapists and sports physiotherapists have internationally recognized professional qualifications.

#Neuron

London, United Kingdom – News Direct – 15 March 2022 – Today, more than 200 civil society organisations – including Climate Action Network, the Clean Lighting Coalition, European Environmental Bureau and South Africa Climate Change Coalition – have sent an open letter to Rosa Vivien Ratnawati, President of the United Nations Minamata Convention on Mercury COP4 demanding the end to exemptions for toxic mercury-containing fluorescent lighting products.

The organisations are calling for a global phase-out of mercury containing fluorescent light products by 2025, in line with a proposed amendment submitted by the African region to the Minamata Convention on Mercury.

As lighting markets in wealthy countries shift to clean LED lighting, less-regulated markets may experience “environmental dumping” of old fluorescent technologies. Many countries in the global North have passed or are considering policies that will ban the sale of mercury-laden, inefficient lighting products in their domestic markets, however they would still allow domestic manufacture and export to less developed and emerging markets.

The import of fluorescents puts the public and environmental health of those countries at unnecessary risk. The proposed amendment by the African region would ensure a global phase-out of fluorescent lighting, eliminating fluorescent lighting at the source by ending the manufacture, export and import of mercury-based lighting products.

The cumulative (2025-2050) global benefits of the African Lighting Amendment would be significant:

• Eliminate 232 tonnes of mercury pollution from the environment, both from the light bulbs themselves and from avoided mercury emissions from coal-fired power plants;
• Reduce global electricity use by 3%;
• Avoid 3.5 gigatonnes of CO2 emissions cumulatively between 2025-2050; equivalent to removing all passenger cars globally from the road for a whole year; and
• Save US$1 trillion on electricity bills

Despite significant progress to reduce mercury, the Minamata Convention includes special exemptions for mercury-based fluorescent lighting products. While these fluorescent exemptions may have been necessary in 2013 when the Convention was drafted, lighting technology has moved on rapidly – and today, the accessibility and affordability of mercury-free LED retrofit lamps makes the fluorescent lamp exemption unnecessary.

The signatories, representing climate and environment advocates, healthcare networks, youth groups, lighting industry representatives and energy experts from across the world are calling for an end to the sale of toxic, polluting lighting products to protect both people and the planet.

“Ending exemptions for mercury-added fluorescent lighting at COP4.2 of the Minamata Convention on Mercury on March 21 and removing 3.5GT of carbon dioxide emissions between 2025-2050 is the quickest win and lowest hanging fruit for climate mitigation,” said Nithi Nesadurai, Director and Regional Coordinator, Climate Action Network Southeast Asia during a media advisory on March 14. “It will be beneficial from the cost, health and environmental perspectives as well. It has to be done now; there is no time to lose.”

The letter comes as research from the Clean Lighting Coalition and partners demonstrate the health risks of mercury in lighting – particularly to vulnerable groups like developing fetuses, babies, and children; workers who handle fluorescent lamps at manufacturing and recycling facilities, as well as maintenance workers in commercial and institutional buildings; and communities of color and people living in low-income neighborhoods who may be chronically exposed to a combination of toxic substances, including mercury.

The letter underscores that the phase-out of fluorescents must be a coordinated global effort. From 21-25 March 2022, the Minamata Convention will host the fourth Conference of Parties (COP4). To enter into effect, the amendment must be passed with a majority consensus of the 137 Parties (countries) to the Convention.

NOTES TO THE EDITOR

1. The Minamata Convention is a global treaty to protect human health and the environment from the adverse effects of mercury – a neurotoxin that can cause harmful and long-term health effects. The Convention launched in 2013 with the goal to “Make Mercury History” by eliminating the use of mercury in products and processes worldwide. Major highlights include a ban on new mercury mines and phase-out of existing ones, control measures on emissions to air and on releases to land and water, and the regulation of the informal sector of artisanal and small-scale gold mining. Currently, 137 parties (countries) have ratified the Convention.
2. Please read the full open letter and full list of signatories here.

About the Climate Action Network

The Climate Action Network (CAN) is the world’s largest climate network made up of over 1,500 civil society organisations in over 130 countries, together fighting the climate crisis. To learn more, visit https://climatenetwork.org/.

About the Clean Lighting Coalition
The Clean Lighting Coalition is a global partnership coordinated by CLASPto capture the health and environmental benefits of eliminating mercury-based lighting. To learn more, visit www.cleanlightingcoalition.organd follow the Coalition on Twitter, Facebook, and LinkedIn.

The issuer is solely responsible for the content of this announcement.

Victoria’s rail transport system modernises infrastructure to increase efficiencies and support cost-effective solutions to their end customers

BRISBANE, AUSTRALIA – News Direct – 15 March 2022 – CSG^® (NASDAQ: CSGS) is transforming the way companies engage with their customers by arming today’s leading brands with future-ready, innovative solutions that drive extraordinary customer experiences. Recently VicTrack, the state-owned enterprise that manages public transport infrastructure in Victoria, Australia, deployed CSG’s configure, price and quote (CPQ) and order management solution to support the digital transformation and automation of its telecommunications network. With CSG’s industry-leading platform, VicTrack’s existing network and processes now deliver more efficient and cost-effective solutions to their end transport, government and wholesale customers.

“VicTrack’s focus is on broad transformation and CSG’s ability to automate our systems and create faster more efficient solutions for our customers is a game-changer for our business,” said Bruce Moore, Executive General Manager, Telecommunications at VicTrack. “We wanted a technology provider that had both local market experience and the proven expertise to handle the complexities of our project. CSG’s flexibility and transparency created a highly collaborative environment that ultimately set our business up for immediate and long-term success.”

CSG technologies enable VicTrack to support the delivery of improved telecommunications solutions both now and into the future, across both public and enterprise applications.

Since implementing CSG’s CPQ solution, VicTrack has:

• Supported the development of a future-proof network: Anticipating the future needs of VicTrack’s business, the high-capacity network is now ready for turnkey upgrades and increasing stakeholder demands.
• Improved process speeds by 30%: Process and deployment times cut by nearly a third, allowing VicTrack to have better visibility across its offerings and make strategic decisions on future services.
• Sparked new revenue opportunities: VicTrack can wholesale excess capacity across its network to other carriers to support them in providing services to the broader state of Victoria.

“By supporting critical rail operations, including ticketing, communications, signalling and video surveillance, the state of Victoria is providing services that keep the heart of the city, its people and businesses, moving,” said Ian Watterson, head of CSG’s Asia-Pacific business. “VicTrack’s progressive approach to digitally transform its network and ensure it is highly efficient and modern is no easy feat. It’s been a privilege to work alongside VicTrack on this journey as CSG continues to deliver disruptive innovation that meets the growing demands of the market to create a more future-ready world.”

Delivered as part of CSG Encompass, a SaaS, open, integrated and modular solution that reduces the complexity of multi-sided, B2B2X ecosystems, CSG’s CPQ solution accelerates time to market with an end-to-end, open and interoperable design that is completely catalog-driven. For more information visit, www.csgi.com/capabilities/revenue-and-customer-management/configure-price-quote-and-order/.

About CSG

CSG is a leader in innovative customer engagement, revenue management and payments solutions that make ordinary customer experiences extraordinary. Our cloud-first architecture and customer-obsessed mindset help companies around the world launch new digital services, expand into new markets, and create dynamic experiences that capture new customers and build brand loyalty. For 40 years, CSG’s technologies and people have helped some of the world’s most recognizable brands solve their toughest business challenges and evolve to meet the demands of today’s digital economy with future-ready solutions that drive exceptional customer experiences. With 5,000 employees in over 20 countries, CSG is the trusted technology provider for leading global brands in telecommunications, retail, financial services, and healthcare. Our solutions deliver real world outcomes to more than 900 customers in over 120 countries.

To learn more, visit us at csgi.com and connect with us on LinkedIn and Twitter.

Copyright © 2022 CSG Systems International, Inc. and/or its affiliates (“CSG”). All rights reserved. CSG® is a registered trademark of CSG Systems International, Inc. All third-party trademarks, service marks, and/or product names which are referenced in this document are the property of their respective owners, and all rights therein are reserved.

#CSG

The issuer is solely responsible for the content of this announcement.

• Financing round led by Prosnav Capital, a strategic international investor based in Luxembourg and Hong Kong, and supported by investment from a group of continuing shareholders
• Financing accelerates the company’s development into a global leader in proteomics and provides direct access to Asian market opened through broad network of Prosnav Capital
• New management team appointed to drive aggressive growth, brings extensive international industry expertise: new CEO, Dr. Albrecht Läufer is joined by Markus Fehr as designated co-CEO

COLOGNE, GERMANY – EQS Newswire – 14 March 2022 – AYOXXA Biosystems GmbH, active in the development of multiplex protein analysis assays for drug discovery and translational research, today announced the successful closing of a financing round which will provide runway for the coming 3 – 5 years. The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network. Besides Prosnav, a group of existing shareholders participated in the financing.

The funds will be used to drive the global commercialization of AYOXXA’s LUNARIS(TM) platform. The platform is designed to generate high-quality proteomics data using smallest-volume samples. It enables fully scalable quantitative validation of disease-relevant biomarkers and allows for translational research from laboratory to clinic, from mouse model to human, from data to treatment or vaccine.

“We are proud to have attracted Prosnav Capital as a shareholder. Prosnav provides the company with a solid perspective, not only in terms of funding, but also with their valuable relationships and experience, especially in Asia,” said Dr. Albrecht Läufer, AYOXXA’s Chief Executive Officer. “With our LUNARIS(TM) platform, AYOXXA is well positioned to enter the commercial growth phase.”

“We are honored to lead a group of highly regarded life science investors in supporting AYOXXA at this crucial point in the company’s history,” said David Huang, founder of Prosnav Capital. “This is our strategically important investment into the healthcare sector; we are excited by the potential of the LUNARIS(TM) technology to support development of better treatments and vaccines. We will help to establish AYOXXA as a global leader in proteomics”.

“AYOXXA is now well positioned to successfully expand into the Asian market, where nearly half of the more than 600 studies with CAR-T cell therapies are being conducted by utilizing its experience gained through use of the LUNARIS(TM) platform at 1^st tier medical institutions in Europe and the US,” said new designated Co-CEO and China Representative of GHA (German Health Alliance) Markus Fehr.

“Prosnav Capital has recognized the potential of AYOXXA to continue to innovate, particularly for the use of proteomic tools in clinical settings, as well as provide the financial stability to expand the commercial capability of the company. I was pleased to have the support of the leading investors in AYOXXA throughout the financing process and encouraged that several shareholders continue as investors in the company alongside the lead investment of Prosnav Capital,” said Rodney Turner, outgoing CEO of AYOXXA.

Continuing investors led by Wellington Partners and NRW.Bank include b-to-v Partners S.à.r.l.; Rainer Christine Asset Management GmbH.; Equivation-Beteiligungsgesellschaft mbH; Roland Oetker Family Office; Riesner Verwaltungs GmbH, the two Co-Founders of AYOXXA and several other private investors.

New management to drive accelerated commercial growth

As part of the financing transaction, it was agreed that previous Managing Directors will continue to serve the company in new capacities. Rodney Turner (CEO) will advise AYOXXA in the US market, and Dr. Markus Zumbansen (CTO) will continue to serve the company as a CSO and CTO. The new CEO, Dr. Albrecht Läufer, and designated co-CEO Markus Fehr will drive AYOXXA’s accelerated commercial growth.

Dr. Läufer joins AYOXXA bringing more than 35 years of experience from international leadership positions in the biotech and pharmaceutical industries and from vaccines development to the company. Mr. Fehr is an expert on the Chinese healthcare market and will retain his position as China representative of the GHA – German Health Alliance, in addition to his role at AYOXXA.

About Prosnav Capital

Prosnav Capital manages over $1 billion in committed capital through its multi-asset class platform, which includes private equity, real estate, structured investments and finance, and asset management. Prosnav has carefully selected high quality fund investment opportunities from around the world and offered them to high-net-worth clients. At the same time, the company actively explores direct and co-investment opportunities. In addition, the company provides comprehensive value-added services throughout the investment cycle, from fundraising inception to investment, post-investment management and exit. In addition to its Luxembourg fund office, which serves as a hub for the EU, Prosnav has offices in key financial centers, including Germany, Switzerland, Canada, the UK (advisory services at the StepStone office), Singapore, Australia, Hong Kong and China. Prosnav employs over 70 people worldwide.

About AYOXXA

AYOXXA Biosystems GmbH, originally a Startup of the National University of Singapore, is an international life science company based in Cologne (Germany) with an office in the USA. AYOXXA enables its customers and partners to utilize its reliable and optimized platform technology to fuel breakthroughs in all areas of life science research and to enhance success in translational science.

With LUNARIS(TM), its proprietary beads-on-a-chip multiplexing platform for advanced protein analysis, the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and drug development. With its advantages in terms of quality, flexibility, robustness and efficiency, LUNARIS(TM) enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker assays, with a focus on the biology of inflammation and immune response.

For more information, visit www.ayoxxa.com.
Follow AYOXXA on LinkedIn.

#AYOXXA

The issuer is solely responsible for the content of this announcement.